Tcelna is currently under active research by Opexa, showing promising results [REF].
Some PPMS patients with a special biomarker (Immunoglobulin M oligoclonal bands) have been shown to respond to standard RRMS medications, though there is only preliminary evidence waiting to be confirmed[REF] .